News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Grants Priority Review To GlaxoSmithKline’s Tykerb
November 17, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Nov. 16 (Bloomberg) -- GlaxoSmithKline Plc said the U.S. Food and Drug Administration gave fast-track status to its application for the experimental drug Tykerb for breast cancer, the most common cancer among women.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
GSK
MORE ON THIS TOPIC
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
·
1 min read
·
Jef Akst
Regulatory
FDA opens Operation TrialBlazer for applications, hoping to reshore early trials
September 15, 2026
·
1 min read
·
Heather McKenzie
Regulatory
Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII meeting
September 15, 2026
·
6 min read
·
Heather McKenzie
IN PARTNERSHIP WITH VIVA BIOTECH
Cyclic peptides open new drug frontiers, if manufacturing can keep up
September 14, 2026
·
6 min read
·
Jennifer C. Smith-Parker
